Clinical Scorecard: FDA approves at-home dexmedetomidine for acute agitation
At a Glance
Category
Detail
Condition
Acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder
Key Mechanisms
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist.
Target Population
Adults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder
Care Setting
At-home self-administration during agitation episodes; dexmedetomidine was previously approved for use under health care provider supervision.
Key Highlights
The FDA approved dexmedetomidine (Igalmi) sublingual film for at-home treatment of acute agitation in the specified adult populations.
The approval was supported by SERENITY At-Home, a phase 3 randomized, double-blind, placebo-controlled safety and tolerability trial.
The trial included 208 treated adults and 2,437 agitation episodes across both treatment groups.
The trial was not powered to assess efficacy, although the study poster reported higher rates of complete agitation resolution with dexmedetomidine than placebo.
Reported safety concerns include hypotension, orthostatic hypotension, and bradycardia.
Guideline-Based Recommendations
Diagnosis
Management
The FDA approved dexmedetomidine sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.
Monitoring & Follow-up
Risks
The source identifies hypotension, orthostatic hypotension, and bradycardia as safety concerns, and lists cardiovascular conditions, history of syncope, hepatic impairment, and concomitant sedating medications as relevant precautions.
In SERENITY At-Home, somnolence, including fatigue, was reported after the first treated episode in 22.5% of dexmedetomidine recipients and 17% of placebo recipients; dry mouth in 6.9% and 0.9%, respectively; and dizziness in 4.9% and 0.9%, respectively.
Patient & Prescribing Data
Adults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
The at-home indication is for self-administration during agitation episodes. In the 12-week trial, tolerability was reported as consistent during repeat dosing; no dexmedetomidine recipients discontinued because of adverse events.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.